Cardiome Pharma (CRME) falls on Canada submission

July 22, 2015 10:55 AM | 12 seconds read | Make a Comment

Cardiome Pharma Corp.

CRME

shares dropped 1.6% to $8.49, on word the company has submitted a Supplemental New Drug Submission (sNDS) to Health Canada's Therapeutic Products Directorate for AGGRASTAT® (tirofiban hydrochloride). Share volume totaled 8,700

Market News and Data brought to you by Benzinga APIs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cardiome Pharma (CRME) falls on Canada submission